Major clinical research advances in gynecologic cancer in 2012.
- Author:
Dong Hoon SUH
1
;
Jae Weon KIM
;
Kidong KIM
;
Hak Jae KIM
;
Kyung Hun LEE
Author Information
- Publication Type:Review
- Keywords: Bevacizumab; PARP inhibitor; Low-risk endometrial cancer; Image-based high-dose rate brachytherapy; Practice guidelines
- MeSH: Achievement; Adenosine Diphosphate; Antibodies, Monoclonal, Humanized; Appointments and Schedules; Bevacizumab; Brachytherapy; Breast Neoplasms; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Metastasis; Nitriles; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrethrins; Receptor, Epidermal Growth Factor; Recombinant Fusion Proteins; Recurrence; Sentinel Lymph Node Biopsy; Sirolimus; Uterine Cervical Neoplasms; Vulvar Neoplasms
- From:Journal of Gynecologic Oncology 2013;24(1):66-82
- CountryRepublic of Korea
- Language:English
- Abstract: Ten topics were chosen among major clinical research achievements in gynecologic oncology in 2012. For ovarian cancer, comprehensive review of the history of bevacizumab studies was followed by poly adenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitors and other molecular targeted agents such as epidermal growth factor receptor tyrosine kinase inhibitor and AMG 386. For the development of genomic study in gynecologic cancers, BRCA and DICER1 mutations were covered in epithelial and nonepithelial ovarian cancer, respectively. For endometrial cancer, targeted agents including mammalian target of rapamycin (mTOR) inhibitors and bevacizumab were discussed. Radiation therapy "sandwiched" between combination chemotherapy schedules for the treatment of uterine papillary serous carcinoma was also reviewed. Preoperative prediction of lymph node metastasis, definition of low-risk group, and recurrence and survival outcomes of laparoscopic approaches were addressed. For cervical cancer, we reviewed long-term benefit of human papillomavirus test and efficacy of paclitaxel/carboplatin versus paclitaxel/cisplatin in stage IVB, persistent or recurrent disease. In addition, the effect of three dimensional image-based high-dose rate brachytherapy was also reviewed. For vulvar cancer, the diagnostic value of sentinel lymph node biopsy was discussed. For breast cancer, positive results of three outstanding phase III randomized clinical trials, CLEOPATRA, EMILIA, and BOLERO-2 were introduced. Lastly, updates of major practice guidelines were summarized.
